Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2017

Description: “Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2017” provides in depth insights on the pipeline drugs and their development activities around the Peripheral T-Cell Lymphomas (PTCL). This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Peripheral T-Cell Lymphomas (PTCL). This report also assesses the Peripheral T-Cell Lymphomas (PTCL) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please Note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope:
- The report provides competitive pipeline landscape of Peripheral T-Cell Lymphomas (PTCL)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Peripheral T-Cell Lymphomas (PTCL) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time: 2 Working Days.

Contents: Peripheral T-Cell Lymphomas (PTCL) Overview
Peripheral T-Cell Lymphomas (PTCL) Pipeline Therapeutics
Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Development by Companies
Peripheral T-Cell Lymphomas (PTCL) Filed and Phase III Products
Comparative Analysis
Peripheral T-Cell Lymphomas (PTCL) Phase II Products
Comparative Analysis
Peripheral T-Cell Lymphomas (PTCL) Phase I and IND Filed Products
Comparative Analysis
Peripheral T-Cell Lymphomas (PTCL) Discovery and Pre-Clinical Stage Products
Comparative Analysis
Drug Candidate Profiles
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
Peripheral T-Cell Lymphomas (PTCL) - Dormant Products
Companies Involved in Therapeutics Development for Peripheral T-Cell Lymphomas (PTCL)
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), 2017
Number of Products under Development by Companies
Comparative Analysis by Filed and Phase III Products, 2017
Comparative Analysis Phase II Products, 2017
Comparative Analysis Phase I and IND Filed Products, 2017
Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
Drug Candidates Profiles
Peripheral T-Cell Lymphomas (PTCL) Assessment by Monotherapy Products
Peripheral T-Cell Lymphomas (PTCL) Assessment by Combination Products
Peripheral T-Cell Lymphomas (PTCL) Assessment by Route of Administration
Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Route of Administration
Peripheral T-Cell Lymphomas (PTCL) Assessment by Molecule Type
Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Molecule Type
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Discontinued Products
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Dormant Products
Products under Development by Companies, 2017

List of Figures
Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), 2017
Filed and Phase III Products, 2017
Phase II Products, 2017
Phase I and IND Filed Products, 2017
Discovery and Pre-Clinical Stage Products, 2017
Peripheral T-Cell Lymphomas (PTCL) Assessment by Monotherapy Products
Peripheral T-Cell Lymphomas (PTCL) Assessment by Combination Products
Peripheral T-Cell Lymphomas (PTCL) Assessment by Route of Administration
Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Route of Administration
Peripheral T-Cell Lymphomas (PTCL) Assessment by Molecule Type
Peripheral T-Cell Lymphomas (PTCL) Assessment by Stage and Molecule Type

Ordering: Order Online - http://www.researchandmarkets.com/reports/4037388/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2017
Web Address: http://www.researchandmarkets.com/reports/4037388/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) Single User</td>
<td>✔️</td>
<td>USD 1250</td>
</tr>
<tr>
<td>Electronic (PDF) Site License</td>
<td>✔️</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) Enterprisewide</td>
<td>✔️</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof] [ ]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World